---
type: "WebPage"
title: "N-glycans analysis laboratory  "
description: "As a biopharmaceutical manufacturer you would like to carry out an analysis of n-glycans What are n-glycans? N-Glycans are complex carbohydrate structures (glycans) covalently attached to proteins via an asparagine residue (N-glycosylation). This type of post-translational modification plays a crucial..."
resource: "https://filab.fr/en/sectors-of-activity/biopharmaceutical/n-glycans-analysis/"
tags: ["EN", "pll_67accb634b55d", "Anaïs DECAUX"]
timestamp: "2026-03-11T14:19:03Z"
published: "2025-02-13T07:49:40Z"
language: "en"
author: "Laure Durieux"
---

# N-glycans analysis laboratory  

## As a biopharmaceutical manufacturer you would like to carry out an analysis of n-glycans

### What are n-glycans?

**N-Glycans** are complex carbohydrate structures (glycans) covalently attached to proteins via an asparagine residue (N-[glycosylation](https://filab.fr/en/sectors-of-activity/biopharmaceutical/glycosylation-analysis.md)). This type of post-translational modification plays a crucial role in protein stability, solubility, function and immunogenicity.

### Classification of N-glycans

  Complex N-Glycans: contain sialic acid residues and are involved in cellular interactions. Hybrid N-Glycans: exhibit a combination of complex motifs and basic structures. Paucimannosidic N-glycans: present in particular in certain organisms and involved in specific functions.
### Why do an n-glycan analysis?

**N-Glycans** are particularly studied in **biopharmaceuticals**, notably for the characterization of monoclonal **antibodies** ([mAbs](https://filab.fr/en/sectors-of-activity/biopharmaceutical/biotherapeutic-recombinant-protein-characterization/analysis-characterization-monoclonal-antibodies-mabs.md)) and**therapeutic proteins**, where their glycosylation profile directly impacts the efficacy and safety of treatments.

N-Glycans play a key role in many biological processes and directly impact the stability, efficacy and immunogenicity of biomolecules, particularly in the pharmaceutical and biotechnology sectors. A precise analysis of these glycosylated structures is essential for the development and quality control of biomedicines, as well as to meet current regulatory requirements.

## FILAB supports biopharmaceutical manufacturers in the analysis of n-glycans

### Why choose FILAB for n-glycans analysis?

FILAB, an analytical expertise laboratory, offers analysis services for your N-Glycans using cutting-edge techniques adapted to industrial constraints and regulatory requirements. Our analytical approach allows us to identify, quantify and characterize the glycosylation profiles of your samples to guarantee the compliance of your products.

## Our analysis services

Identification and fine characterization of glycosylated structures

Complementary structural characterization

Characterization of therapeutic [glycoproteins](https://filab.fr/en/sectors-of-activity/biopharmaceutical/biotherapeutic-recombinant-protein-characterization/analysis-characterization-glycoproteins.md), [biosimilars](https://filab.fr/en/sectors-of-activity/biopharmaceutical/biotherapeutic-recombinant-protein-characterization/analysis-characterization-biosimilars.md) and [vaccines](https://filab.fr/en/our-services/our-expertise-services/laboratory-analysis-injectable-drugs/laboratory-for-the-analysis-of-injectable-products-and-pharmaceutical-vaccines.md).

[Intact mass analysis](https://filab.fr/en/sectors-of-activity/biopharmaceutical/intact-mass-analysis-laboratory.md)

[Elucidation of the structure of carbohydrates](https://filab.fr/en/sectors-of-activity/biopharmaceutical/carbohydrate-analysis-glycosylation-characterization.md)

Identification des sites de glycosylation

Separation and analysis of derivatized glycans

[Glycosylation analysis](https://filab.fr/en/sectors-of-activity/biopharmaceutical/glycosylation-analysis.md)

Study of glycans in bioactive [peptides](https://filab.fr/en/sectors-of-activity/biopharmaceutical/biotherapeutic-recombinant-protein-characterization/peptide-analysis-biopharmaceutical-services.md) and [proteins](https://filab.fr/en/sectors-of-activity/biopharmaceutical/biotherapeutic-recombinant-protein-characterization/protein-analysis.md)

[Peptide aggregation analysis](https://filab.fr/en/sectors-of-activity/biopharmaceutical/peptide-aggregation-analysis-laboratory.md)

[Study of monosaccharide composition](https://filab.fr/en/sectors-of-activity/biopharmaceutical/monosaccharide-structure-analysis-laboratory.md)

[UPLC](https://filab.fr/en/our-technical-resources/laboratory-analysis-uplc.md)

[IRTF](https://filab.fr/en/our-technical-resources/laboratory-analysis-ftir-spectroscopy.md)

[LC-MS](https://filab.fr/en/our-technical-resources/altis-lc-msms-analysis.md)

[RMN](https://filab.fr/en/our-technical-resources/laboratory-analysis-nmr.md)

  ![analyse n-glycans](https://filab.fr/wp-content/uploads/2024/10/shutterstock_1736709881-mabs.jpg)